BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

A Market Review of DNA-encoded Libraries Technology in Drug Discovery

by Irina Bilous , Andrii Buvailo, PhD  (contributor ) , Natalia Honchar  (contributor )   •   Oct. 5, 2022  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   Biopharma insight    # Tools & Methods   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

(Last updated: October 05, 2022)

The interest of pharma organizations in DNA-encoded chemical libraries (DEL) technology has been growing over the years, with numerous pharma organizations now having their internal screening programs using DELs or outsourcing capabilities from specialized DEL providers.

This report provides a bird's view of the DEL market, including a summary of DEL technology benefits and limitations, key players, major research deals, and several examples of successful hit discovery programs using DELs. 

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Historical context

The concept of DNA-encoded libraries (DEL) appeared in the early 1990th when scientists from Scripps Research Institute published a paper on “Encoded combinatorial chemistry.” The main principle of DEL technology is to encode each compound in the library with a unique DNA barcode. Thereby library of billion compounds can be screened as a mix in a single test tube, and the active compounds are identified by amplification and sequencing of the DNA  barcodes. 

At the initial stage, companies pioneering DEL development faced a lack of suitable methods for DNA sequencing. Scientists from Praecis Pharmaceuticals then founded a company that managed to sequence DEL libraries. Praecis and Nuevolution were the first to have taken a chance on DEL in the 2000s. In 2005 and subsequent years, second-generation sequencing emerged, making DEL a much more attractive and economically feasible approach to drug discovery. 

 

An overview of DEL technology

DEL technology comes from the merge of DNA encoding and combinatorial chemistry. The most popular method to build DEL is the “split and pool” approach. At the first step of the synthesis, chemical building blocks (BBs) are tagged with DNA barcodes. In the second step, they are mixed and then split into different portions. Next, a new set of building blocks is added to the chemical reaction, and then corresponding DNA barcodes are attached and linked with previous DNA molecules. Thus, DNA encodes each step of chemical synthesis for each compound. 


* Reproduced from C&EN

 


Size and costs of DELs

The “Split and pool” method enables to build of libraries containing up to 10^10 compounds. For example, HitGen’s libraries contain 400 billion molecules, X-chem provides 200 million compounds for screening, and Nuevolution has assembled a collection of 40 trillion compounds. To compare, the size of a common HTS library is restricted to several million compounds due to the prohibitive cost of synthesizing and managing more extensive collections. Overall, the cost of creating and screening an HTS library of 1 million compounds would cost millions of dollars  (approximately $1,100 per compound), while screening a DEL library of 800 thousand compounds would cost on the order of $150.000. 

 

Hit discovery using DELs

Screening of the DELs is conducted in single test tubes, where the target protein is incubated with a library. The target proteins can be anchored on a solid support, commonly magnetic beads.  After thorough washing, only high-affinity ligands remain associated with a target. After DNA sequencing and decoding of the structure of active compounds, the last should be resynthesized to repeat the affinity binding assay. A lot of different selection strategies can be applied, even phenotypic screening is compatible with DELs.

DEL is suitable for the synthesis and screening of small molecules, macrocyclic compounds, and peptides. Scientists are harnessing the chemical properties of DNA, especially the principle of complementarity, to develop new design.

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: Tools & Methods   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

The Evolution Of Pharmaceutical R&D Model
by Andrii Buvailo
Democratizing Artificial Intelligence For Pharmaceutical Research
by Andrii Buvailo
[White paper] High Throughput Quantum Chemistry for Drug Discovery - Towards Reaction Screening
by Peter Jarowski

 

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.